Xiao Wenjing, Guo Jian-Ping, Li Chun, Ye Hua, Wei Wei, Zou Yaohong, Dai Lie, Li Zhijun, Zhang Miaojia, Li Xiangpei, Cai Xiaoyan, Zhao Jianhong, Wang Youlian, Tao Yi, Liu Dongzhou, Li Yasong, Wu Min, Sun Erwei, Wu Lijun, Luo Li, Mu Rong, Li Zhanguo
Department of Rheumatology & Immunology, People's Hospital, Peking University, Beijing, PR China.
Department of Rheumatology & Immunology, Tianjin Medical University General Hospital, Tianjin, PR China.
Pharmacogenomics. 2018 Apr;19(5):383-392. doi: 10.2217/pgs-2017-0162. Epub 2018 Mar 8.
Iguratimod (IGU) is a novel disease-modifying anti-rheumatic drug (DMARD) in rheumatoid arthritis (RA). Like other DMARDs, IGU exhibited significant differences in effectiveness and safety.
The aim of this study was to identify genetic predictorsof efficacyand toxicity of IGU in patients with RA.
MATERIALS & METHODS: Seven SNPs from IGU-metabolizing genes were genotyped in 272 IGU-treated patients with RA. Results: ABCG2 rs2231142 A allele conferred a higher response to IGU, while NAT2 rs1495742 G carriersconferred a lower response to IGU. CYP2C19*2 rs4244285 A carriers had higher risk for IGU-induced toxicity compared to the GG carriers.
Our study suggests that the polymorphisms of ABCG2 (rs2231142), NAT2 (rs1495741)and CYP2C19*2 (rs4244285) may help to predict thetherapeutic effectiveness and toxicity of IGU in patients with RA.
艾拉莫德（IGU）是类风湿性关节炎（RA）中一种新型的改善病情抗风湿药（DMARD）。与其他DMARDs一样，IGU在有效性和安全性方面存在显著差异。
本研究旨在确定IGU在RA患者中的疗效和毒性的遗传预测指标。
对272例接受IGU治疗的RA患者进行了IGU代谢基因的7个单核苷酸多态性（SNP）基因分型。结果：ABCG2 rs2231142 A等位基因对IGU的反应较高，而NAT2 rs1495742 G携带者对IGU的反应较低。与GG携带者相比，CYP2C19*2 rs4244285 A携带者发生IGU诱导毒性的风险更高。
我们的研究表明，ABCG2（rs2231142）、NAT2（rs1495741）和CYP2C19*2（rs4244285）的多态性可能有助于预测IGU在RA患者中的治疗效果和毒性。
